SCHEMBL14386902

SCHEMBL14386902

COc1ccc(C2CCN(CC(O)C3CCN(C(=S)Nc4cc(OC)cc(OC)c4)CC3)CC2)cc1

nearest known ligand 0.53

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 4/20 0.53
▸ MEN1 O00255 2/20 0.53
▸ RAB9A P51151 2/20 0.51
▸ NPC1 O15118 1/20 0.51
▸ SMN1; SMN2 Q16637 3/20 0.48
▸ LMNA P02545 2/20 0.48
▸ GAA P10253 2/20 0.48
▸ ALOX12 P18054 1/20 0.48
▸ KDM4E B2RXH2 1/20 0.48
▸ ALDH1A1 P00352 2/20 0.48
▸ DRD2 P14416 1/20 0.46
▸ PKM P14618 1/20 0.46
▸ MAPT P10636 1/20 0.46
▸ TDP1 Q9NUW8 1/20 0.46
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ LHCGR P22888 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14387010 0.92 KMT2A (0.50) KMT2AMEN1RAB9ANPC1SMN1; SMN2
SCHEMBL14430084 0.92 KMT2A (0.50) KMT2AMEN1RAB9ANPC1SMN1; SMN2
SCHEMBL14430076 0.92 RAB9A (0.61) KMT2AMEN1RAB9ANPC1LMNA
SCHEMBL14430081 0.88 LMNA (0.51) KMT2AMEN1RAB9ANPC1SMN1; SMN2
SCHEMBL14430082 0.87 MAPT (0.55) KMT2AMEN1RAB9ANPC1SMN1; SMN2
SCHEMBL14387007 0.87 RAB9A (0.52) KMT2AMEN1RAB9ANPC1GAA
SCHEMBL14430083 0.86 KMT2A (0.53) KMT2AMEN1RAB9ANPC1SMN1; SMN2
SCHEMBL14430079 0.86 KMT2A (0.48) KMT2AMEN1RAB9ANPC1SMN1; SMN2
SCHEMBL14387083 0.85 KMT2A (0.47) KMT2AMEN1RAB9ANPC1SMN1; SMN2
SCHEMBL14430080 0.85 MEN1 (0.54) KMT2AMEN1RAB9ANPC1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007130712-A1 SUBSTITUTED DIPIPERIDINE AS CCR2 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES JANSSEN PHARMACEUTICA, NV (BE) 2007-11-15 — — WO disclosed
US-20070197590-A1 SUBSTITUTED DIPIPERIDINE CCR2 ANTAGONISTS JANSSEN PHARMACEUTCA N.V. (BE) 2007-08-23 — — US disclosed
US-20070197590-A1 SUBSTITUTED DIPIPERIDINE CCR2 ANTAGONISTS JANSSEN PHARMACEUTCA N.V. (BE) 2007-08-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197590-A1 SUBSTITUTED DIPIPERIDINE CCR2 ANTAGONISTS CCR2, CCR1, CCR5 KMT2A 2990/4885MEN1 4602/4885RAB9A 3799/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback